Nothing said here yet.
to join the conversation.
| Morano Susan EDirector | Buy | 2,040 | $100.4K | Tue, Aug 25 |
| Kevin Hern | Sell | $75.0K | Wed, Sep 9 | Tue, Sep 15 |
| Kevin Hern | Sell | $75.0K | Fri, Sep 4 | Tue, Sep 15 |
| Kevin Hern | Sell | $24.0K | Thu, Sep 3 | Tue, Sep 15 |
| Kevin Hern | Sell | $32.5K | Mon, Aug 31 | Tue, Sep 15 |
| Gilbert Cisneros | Buy | $8.0K | Tue, Aug 18 | Fri, Sep 4 |
| Alan Armstrong | Buy | $8.0K | Fri, Mar 27 | Tue, Jul 21 |
| John Boozman | Sell | $8.0K | Thu, Jun 4 | Mon, Jul 13 |
| Gilbert Cisneros | Sell | $8.0K | Fri, Jun 5 | Thu, Jul 2 |
| Gilbert Cisneros | Buy | $8.0K | Fri, Jun 5 | Thu, Jul 2 |
| Gilbert Cisneros | Buy | $8.0K | Fri, May 29 | Fri, Jun 5 |
| Gilbert Cisneros | Buy | $8.0K | Tue, May 19 | Fri, Jun 5 |
| Gilbert Cisneros | Buy | $8.0K | Mon, May 11 | Fri, Jun 5 |
Intuitive Surgical's surging robotic surgery demand and stronger earnings momentum make it a better buy than Boston Scientific despite its valuation premium.
Boston Scientific reported Q3 2026 sales of US$5,138 million and net income of US$582 million, alongside impairment charges and a reduced full year outlook after a prior cyberattack disrupted manufacturing and shipments.
Boston Scientific (NYSE: BSX) reported new FDA clearances for urology technologies and an advanced intravascular lithotripsy system. The business enrolled the first patient in the Elite AF clinical trial for its next generation WATCHMAN device.
Boston has a growing body of evidence across AF and stroke prevention with studies, including CHAMPION-AF, BEAT AF, OPTION, and AVANT GUARD.
For questions about this article or underlying research, email [email protected].
Boston Scientific faces a challenging 2027 as cybersecurity disruptions, EP and WATCHMAN weakness and China pricing pressures weigh on growth prospects.
Boston Scientific (BSX) moved into focus after third quarter 2026 results, as modest sales of US$5.14b and net income of US$582m met a sharply lower market reaction and fresh earnings guidance.
Boston Scientific’s weak outlook, cyberattack disruptions, and slowing Watchman and electrophysiology growth weighed on sentiment.
Boston Scientific (NYSE:BSX) reported third-quarter 2026 results that fell below its prior guidance after a cybersecurity incident disrupted manufacturing and product shipments for eight business days, while competitive and pricing pressures weighed on key…
Boston Scientific stock took a hit today, sliding almost 6% to about US$42 after investors reacted to its Q3 2026 report.
Cost cuts and pipeline launches aim to restore growth momentum after 2027 headwinds flatten earnings.
Shares of medical device company Boston Scientific (NYSE:BSX) fell 8% in the morning session after the company reported third-quarter 2026 financial results showing net sales growth of 1.5 percent and highlighted efforts to restore operations following a…